References
- 1. STEWART, S., HART, C.L., HOLE, D.J., MCMURRAY, J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001 m.; 86(5):516–21.
- 2. KLOOSTERMAN, M., CRIJNS, H.J.G.M., VAN GELDER, I.C. Rising prevalence of atrial fibrillation in the elderly population: New challenges of geriatric cardiology. Europace 2019 m.; 21(10):1451–1453.
- 3. BENJAMIN, E.J., MUNTNER, P., ALONSO, A., BITTENCOURT, M.S., CALLAWAY, C.W., CARSON, A.P., et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association,b.n.,B.m.,2019 m.
- 4. LIP, G.Y.H., BRECHIN, C.M., LANE, D.A. The global burden of atrial fibrillation and stroke: A systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012 m.; 142(6):1489–1498.
- 5. BENJAMIN, E.J., WOLF, P.A., D’AGOSTINO, R.B., SILBERSHATZ, H., KANNEL, W.B., LEVY, D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998 m.; 98(10):946–952.
- 6. BALL, J., CARRINGTON, M.J., MCMURRAY, J.J. V, STEWART, S. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. Int. J. Cardiol. 2013 m.; 167(5):1807–1824.
- 7. CHUGH, S.S., HAVMOELLER, R., NARAYANAN, K., SINGH, D., RIENSTRA, M., BENJAMIN, E.J., et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation 2014 m.;129(8):837–847.
- 8. DOUGLAS P. ZIPES, PETER LIBBY, ROBERT O. BONOW, DOUGLAS L. MANN, G.F.T.& E.B. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, Eleventh Edition,Elsevier,B.m.,2018 m.
- 9. STEWART, S., HART, C.L., HOLE, D.J., MCMURRAY, J.J.V. A population-based study of the long-term risks associated with atrial fibrillation: 20-Year follow-up of the Renfrew/Paisley study. Am. J. Med. 2002 m.; 113(5):359–364.
- 10. .KOTECHA, D., PICCINI, J.P. Atrial fibrillation in heart failure: What should we do?. Eur. Heart J. 2015 m.; 36(46):3250–3257.
- 11. LIP, G.Y.H., NIEUWLAAT, R., PISTERS, R., LANE, D.A., CRIJNS, H.J.G.M., ANDRESEN, D., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest 2010 m.; 137(2):263–272.
- 12. Atrial Fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994 m.; 154:1449–1157
- 13. PREVENTION, S., INVESTIGATORS, F. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study. J. Stroke Cerebrovasc. Dis. 1995 m.;5(3):147–157.
- 14. GAGE, B.F., WATERMAN, A.D. Validation of Clinical Classification Schemes for Predicting Stroke Results From the National Registry of Atrial Fibrillation. JAMA J. Am. Med. Assoc. 2001 m.; 285(22):2864–2870.
- 15. PICCINI, J.P., STEVENS, S.R., CHANG, Y., SINGER, D.E., LOKHNYGINA, Y., GO, A.S., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Validation of the R2CHADS2 index in the ROCKET AF. Circulation 2013 m.; 127(2):224–232.
- 16. FU, S., ZHOU, S., LUO, L., YE, P. Clinical Interventions in Aging Dovepress r 2(gFr) ChADs 2 and r 2(gFr) ChA 2 Ds 2 VAsc schemes improved the performance of ChADs 2 and ChA 2 Ds 2 VASc scores in death risk stratification of Chinese older patients with atrial fibrillation. Clin. Interv. Aging 2017 m.; 12–1233.
- 17. FANG, M.C., GO, A.S., CHANG, Y., BOROWSKY, L., POMERNACKI, N.K., SINGER, D.E. Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation 2008 m.
- 18. SINGER, D.E., CHANG, Y., BOROWSKY, L.H., FANG, M.C., POMERNACKI, N.K., UDALTSOVA, N., et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J. Am. Heart Assoc. 2013 m.; 2(3).
- 19. OLDGREN, J., HIJAZI, Z., LINDBÄCK, J., ALEXANDER, J.H., CONNOLLY, S.J., EIKELBOOM, J.W., et al. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation 2016 m.; 134(22):1697–1707.
- 20. HIJAZI, Z., LINDBÄCK, J., ALEXANDER, J.H., HANNA, M., HELD, C., HYLEK, E.M., et al. The ABC (age, biomarkers, clinical history) stroke risk score: A biomarker-based risk score for predicting stroke in atrial fibrillation. Eur. Heart J. 2016 m.; 37(20):1582–1590.
- 21. HIJAZI, Z., OLDGREN, J., ANDERSSON, U., CONNOLLY, S.J., EZEKOWITZ, M.D., HOHNLOSER, S.H., et al. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: A RE-LY substudy. Heart 2014 m.; 100(15):1193–1200.
- 22. SIQUIN YE, MIN QIAN, BO ZHAO, R.B. et al. CHA2 DS2 -VASc Score and Adverse Outcomes in Patients with Heart Failure with Reduced Ejection Fraction and Sinus Rhythm. b.n.Available at: doi:10.1002/ejhf.613.
- 23. BIANCARI, F., ASIM MAHAR, M.A., KANGASNIEMI, O.P. CHADS2 and CHA2DS2-VASc scores for prediction of immediate and late stroke after coronary artery bypass graft surgery. J. Stroke Cerebrovasc. Dis. 2013 m.; 22(8):1304–1311.
- 24. PAOLETTI PERINI, A., BARTOLINI, S., PIERAGNOLI, P., RICCIARDI, G., PERROTTA, L., VALLEGGI, A., et al. CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy. Europace 2014 m.; 16(1):71–80.
- 25. KOEDA, Y., KOMATSU, T., MATSUURA, Y., MORIOKA, H., UCHIMURA, Y., TAGUCHI, Y., et al. CHADS2 and modified CHA2DS2-VASc scores for the prediction of congestive heart failure in patients with nonvalvular atrial fibrillation. J. Arrhythmia 2017 m.; 33(5):488–493.
- 26. MAMAS, M.A., CALDWELL, J.C., CHACKO, S., GARRATT, C.J., FATH-ORDOUBADI, F., NEYSES, L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur. J. Heart Fail. 2009 m.; 11(7):676–683.
- 27. WANG, T.J., LARSON, M.G., LEVY, D., VASAN, R.S., LEIP, E.P., WOLF, P.A., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham heart study. Circulation 2003 m.; 107(23):2920–2925.
- 28. NACCARELLI, G.V., PANACCIO, M.P., CUMMINS, G., T.U., N. CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. Am. J. Cardiol. 2012 m.;109(10):1526–1533.
- 29. CAMELO-CASTILLO, A., RIVERA-CARAVACA, J.M., MARÍN, F., VICENTE, V., LIP, G.Y.H., ROLDÁN, V. Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. Thromb. Haemost. 2020 m.
- 30. ZHU, W., WU, Y., ZHOU, Y., LIANG, W., XUE, R., WU, Z., et al. CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Cardiovasc. Drugs Ther. 2020 m.
- 31. FARIS, R.F., FLATHER, M., PURCELL, H., POOLE-WILSON, P.A., COATS, A.J. Diuretics for heart failure. John Wiley and Sons LtdAvailable at: doi:10.1002/14651858.CD003838.pub4.
- 32. SLIVNICK, J., LAMPERT, B.C. Hypertension and Heart Failure. Elsevier Inc.Available at: doi:10.1016/j.hfc.2019.06.007.
- 33. SORRENTINO, M.J. The Evolution from Hypertension to Heart Failure. Elsevier Inc.Available at: doi:10.1016/j.hfc.2019.06.005.